Christopher Cutie, MD

Articles by Christopher Cutie, MD

Looking Ahead: TAR-200's Evolving Role in NMIBC and Future Directions in Bladder Cancer Care

Christopher Cutie, MDNon-Muscle Invasive Urothelial Carcinoma | December 14, 2024

Dr. Christopher Cutie shares his thoughts on the potential of TAR-200 to redefine care for BCG-unresponsive, HR NMIBC.

The SunRISe Trials and TAR-200: Bladder-Sparing Therapies for NMIBC

Christopher Cutie, MDNon-Muscle Invasive Urothelial Carcinoma | December 14, 2024

Dr. Christopher Cutie describes the innovative TAR-200 system and its role in providing sustained intravesical drug delivery.